Mechanistic study of anti-Platelet therapy in Atherosclerosis (MPA)
Research type
Research Study
Full title
Targeting the Inflammasome with Anti-platelet Therapy: A Mechanistic Study
IRAS ID
342342
Contact name
Ashish Patel
Contact email
Sponsor organisation
King's College London
ISRCTN Number
ISRCTN00000000
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 6 months, 1 days
Research summary
Atherosclerosis is the main cause of heart disease, stroke, and diseases affecting blood flow to the limbs. It happens because of a complex interaction between blood clotting, inflammation, and the body’s immune system. When platelets (cells involved in blood clotting) and monocytes (a type of white blood cell) interact, they form clusters called monocyte platelet aggregates (MPAs), which play a role in inflammation. MPAs are thought to contribute to the inflammation seen in atherosclerosis.
This study aims to understand how common anti-clotting medications, like aspirin and clopidogrel, affect MPAs, monocyte function, and inflammation. Past research has shown inconsistent results due to differences in study conditions, participants, and medication dosages. This research will help us better understand how these medications work and could lead to better ways to use them to slow the progression of atherosclerosis and its complications.
The study is sponsored by King’s College London and Guy's and St Thomas' NHS Foundation Trust.REC name
London - South East Research Ethics Committee
REC reference
25/LO/0362
Date of REC Opinion
30 May 2025
REC opinion
Further Information Favourable Opinion